As of March 1, there were 308 COVID-19 vaccine candidates with 81 in clinical trials, according to a new vaccine trial tracker.

Of those trials, there were 24 in phase 1, 26 in phase 1/2, seven in phase 2, 16 in phase 3 and four in phase 4. Four studies were terminated. Twelve of the tracked vaccines are currently being administered to the public, but trials are ongoing with several of them.

Of the more than 300 vaccine candidates tracked, 38 were RNA-based and 26 were DNA-based. Other vaccine types include nonreplicating vector (37), replicating vector (24), inactivated (20), live-attenuated (4), protein subunit (99), virus-like particle (22) and other/unknown (39).

The statistics come from researchers at the University College London and the London School of Hygiene & Tropical Medicine (LSHTM), which recently launched the trial tracker. It is hosted by the Vaccine Centre at LSHTM and is updated weekly, gathering information on all preclinical and clinical candidates from the World Health Organization’s tracker database, as well as the Milken Institute’s COVID-19 treatment and vaccine tracker. It also includes information provided directly by sponsors.

View the LSHTM tracker here: http://bit.ly/3sNMAZG.